•Roivant, Priovant report positive phase 3 NIU data for brepocitinib•Industry payments tied to higher prescribing volume, costs•FDA approves Xbrane Biopharma's Lucentis biosimilar•AAO Foundation and VSP award over $200K in OD scholarships•FDA updates recall for CooperVision's Sofmed Breathables Advanced Toric contact lenses•Roivant, Priovant report positive phase 3 NIU data for brepocitinib•Industry payments tied to higher prescribing volume, costs•FDA approves Xbrane Biopharma's Lucentis biosimilar•AAO Foundation and VSP award over $200K in OD scholarships•FDA updates recall for CooperVision's Sofmed Breathables Advanced Toric contact lenses
HEADLINES
FEATURED
Oral small molecule is designed to correct protein misfolding for RHO gene mutations, the root cause of RHO-adRP; phase 1/2 clinical study currently underway.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
